Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03334734
Other study ID # PBTZ169-A15-C2A-1
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date December 16, 2016
Est. completion date February 22, 2018

Study information

Verified date February 2020
Source Nearmedic Plus LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multicenter, open, randomized study with active control (isoniazid) to evaluate the early antibacterial activity, safety and pharmacokinetics of the drug PBTZ169 (capsules 80 mg) when used in patients with first-diagnosed tuberculosis of the respiratory system with bacterial excretion and saved bacterial susceptibility to isoniazid and rifampicin


Description:

This phase 2a study is aimed to evaluate the early bactericidal activity of a new anti-tuberculosis drug PBTZ169 (capsules 80 mg), and its results will allow preliminary evaluate antimycobacterial properties of PBTZ169 and confirm a potentially more effective dose for subsequent studies. This study is an open, randomized comparative efficacy (on the parameter of early bactericidal activity), safety and pharmacokinetics study of PBTZ169 in patients with first-diagnosed lung tuberculosis and preserved sensitivity to base antimycobacterial drugs: rifampicin and isoniazid.

Within the framework of the study, it is planned to use the studied drugs (PBTZ169 and isoniazid) as monotherapy within 14 days. Isoniazid is used as a "positive control", that is, in order to determine whether the method of assessing efficacy on the parameter of early bactericidal activity is working.


Recruitment information / eligibility

Status Terminated
Enrollment 16
Est. completion date February 22, 2018
Est. primary completion date September 10, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Written informed consent received from a volunteer

- Men and women aged 18 to 65 years, inclusive

- The first-diagnosed active pulmonary tuberculosis, confirmed by characteristic radiographic changes (infiltration, dissemination, destruction) during radiography or computed tomography of chest organs, without damage to other organs or with the defeat of one or more of the following organs: larynx, trachea, bronchi, lymph nodes

- The amount of sputum given by the patient is sufficient for carrying out the analyzes provided for by the protocol, but not less than 4-5 ml at the screening

- The presence of acid-fast mycobacteria in the sputum according to the results of microscopy of smears (1+ and more using the method of microscopy with luminescent dye staining according to the Order of the Ministry of Health of the Russian Federation of March 21, 2003 No. 109, the last edition) and the detection of the DNA of mycobacteria of tuberculosis by the results of molecular genetic methods of diagnosis

- Body weight not less than 51 kg

- Body mass index of 18.5-25 kg/m2

- Ability, according to investigators opinion, to comply with all requirements of the protocol

- Agreement to use double contraception method during the study participation and for 3 months after the test drug administration - combination of male condom with not less than one of the following methods:

- female partner using hormonal contraception;

- using aerosols, creams, suppositories and other agents containing spermicides;

- female partner using intrauterine device

Exclusion Criteria:

- Extrapulmonary localization of tuberculosis

- Presence of resistance to rifampicin and / or isoniazid in the study of sputum samples using molecular genetic methods

- Admission of any anti-tuberculosis drugs from the moment of diagnosis of tuberculosis to the moment of inclusion in the study

- The presence of absolute indications for surgical treatment of tuberculosis at the time of screening

- Positive tests for serological markers of syphilis or HIV infection during screening; active hepatitis or decompensated hepatic cirrhosis

- Aggravated allergic history, including presence of at least one episode of drug allergy

- The values of renal and / or hepatic parameters according to laboratory analyzes (taking into account the range of normal laboratory values):

- Aspartate aminotransferase (AST) level > 2.0 x upper limit of the norm

- Alanine aminotransferase (ALT) level > 2.0 x upper limit of norm

- General bilirubin level > 1.5 x upper limit of norm

- Creatinine level > 1.5 x upper limit of norm

- Individual drug components intolerance

- Presence in the anamnesis of malignant neoplasms, except for basal cell skin cancer

- The presence of severe chronic somatic diseases in the stage of decompensation, including diseases of the cardiovascular, bronchopulmonary, neuroendocrine system, ear, nose and throat (ENT) organs, the gastrointestinal tract, liver, kidneys, blood, skin, or any other somatic or mental diseases that, according to the researcher, prevent the patient from entering the study

- Gastrointestinal surgeries (except for appendectomy performed not less than 1 year before screening)

- Mental illness that may interfere with the patient's compliance with the protocol

- Diabetes mellitus

- Acute viral and bacterial infections at the time of enrollment or within 2 weeks before enrollment

- Alcoholism (except in cases when the patient is able, in the opinion of the researcher, to refrain from taking alcohol during the period of participation in the study), drug addiction, abuse of medicines

- Positive tests for narcotic and psychotropic agents

- Regular admission or use (including externally) of any hormonal medicines lasting more than 1 week less than 30 days before screening (with the exception of oral hormonal contraceptives and intrauterine spirals containing hormones)

- Use of cytostatic drugs less than 30 days before screening

- Multiple admission of drugs with the described in the instructions for medical use adverse events related to nervous system, hemodynamic and hepatic functions with frequencies "very frequent" (=10%) and "often" (=1% and <10%) less than 21 days before screening

- Pregnancy or lactation period

- Planned conception or sperm donation during the study after the test drug administration or during 3 months after the last date of drug administration

- Participation in other clinical studies of drugs within less than 3 months before the screening

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PBTZ169
Once a day for 14 days
Isoniazid
Once a day for 14 days

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Nearmedic Plus LLC OCT LLC

Outcome

Type Measure Description Time frame Safety issue
Primary Early Bactericidal Activity (0-14) Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): agar inoculation, the mean of two measurements at the Visit 14 days after the onset of monotherapy
Primary Early Bactericidal Activity (0-14) Early bactericidal activity 14 days from the monotherapy start date (EBA 0-14): PCR, the mean of two measurements at the Visit 14 days after the onset of monotherapy
Secondary Early Bactericidal Activity (0-2) EBA (0-2): agar inoculation, the mean of two measurements at the Visit 2 days after the onset of monotherapy
Secondary Early Bactericidal Activity (0-7) EBA (0-7): agar inoculation, the mean of two measurements at the Visit 7 days after the onset of monotherapy
Secondary Early Bactericidal Activity (0-2) EBA (0-2): PCR, the mean of two measurements at the Visit 2 days after the onset of monotherapy
Secondary Early Bactericidal Activity (0-7) EBA (0-7): PCR, the mean of two measurements at the Visit 7 days after the onset of monotherapy
Secondary Peak Plasma Concentration (?max) of PBTZ169 Peak plasma concentration (?max) of PBTZ169 for multiple dosing Up to 72 hours after the last drug administration
Secondary Minimal Plasma Concentration (?min) of PBTZ169 Minimal plasma concentration (?min) of PBTZ169: concentration measurement following single dosing for single dosing , Day 1 (24 h after 1st dose of PBTZ169)
Secondary Residual Concentration (Ctrough) of PBTZ169 Residual concentration (Ctrough) of PBTZ169, measured 24 hours after the first dose administration, prior to the last dose, and 24 hours after the last dose Up to 72 hours after the last drug administration
Secondary Minimal Plasma Concentration (?min) of PBTZ169 Minimal plasma concentration (?min) of PBTZ169: multiple dosing Up to 72 hours after the last drug administration
Secondary Time to Reach Maximum Concentration (Tmax) of PBTZ169 Time to reach maximum concentration (Tmax) of PBTZ169 after single oral administration in different doses for single dosing , Day 1 (24 h after 1st dose of PBTZ169)
Secondary Time to Reach Maximum Concentration (Tmax) of PBTZ169 Time to reach maximum concentration (Tmax) of PBTZ169 after multiple oral administration in different doses Up to 72 hours after the last drug administration
Secondary AUC(0-24) Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours] Up to 24 hours after the first drug administration
Secondary Peak Plasma Concentration (?max) of PBTZ169 Peak plasma concentration (?max) of PBTZ169: concentration measurement following single dosing for single dosing , Day 1 (24 h after 1st dose of PBTZ169)
Secondary AUC(0-24) Area under the plasma concentration of PBTZ169 versus time curve in frames [0-24 hours] for the last dosing (Day 14) Up to 24 hours after the last drug administration
Secondary AUC (0-t) Area under the plasma concentration of PBTZ169 versus time curve in frames [0-last concentration above lower limit of quantification (LLoQ)] Up to 72 hours after the last drug administration
Secondary AUC(0-8) of PBTZ169 Area under the plasma concentration versus time curve in frames [0-8] Up to 72 hours after the last drug administration
Secondary Accumulation Ratios for the PK Parameters AUC(0 -24) Accumulation ratios for the PK parameter AUC(0 -24): AUC(0- 24,ss)/AUC(0 -24), Day 1, on the original scale 24 hours after the first and the last drug administration
Secondary Average Concentration (Css,av) of PBTZ169 Average steady-state concentration in the dosing interval following multiple dosing was evaluated as the ratio AUC0 24/t (t = the dosing interval) Up to 72 hours after the last drug administration
Secondary Fluctuations (%) in the Dosing Interval Fluctuations (%) in the dosing interval after multiple dosing ((Cmax - Cmin) × 100%/Css,av) Up to 72 hours after the last drug administration
Secondary Total (Plasma) Clearance (Clt) of PBTZ169 Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.
24 hours after the first drug administration
Secondary Total (Plasma) Clearance (Clt) of PBTZ169 Clt/F (apparent total clearance following single and multiple oral administration) was calculated using the following formula:
Cl_t/F=D/AUC where D is the daily dose of the drug.
24 hours after the last drug administration
Secondary Volume of Distribution (Vd) of PBTZ169 Distribution volume Vd for a dosing interval of 72 hours after the last dose Up to 72 hours after the last drug administration
Secondary Plasma Half-life Time (T1/2) of PBTZ169 24 hours after the fist drug administration
Secondary Plasma Half-life Time (T1/2) of PBTZ169 24 hours after the last drug administration
Secondary Elimination Constant (Kel) of PBTZ169 Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve. 24 hours after the first drug administration
Secondary Elimination Constant (Kel) of PBTZ169 Apparent terminal elimination rate constant was evaluated based on the regressional dependence of log-transformed concentrations ln(C) on time for the terminal log- linear part of the concentration-time curve. 72 hours after the last drug administration
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2